Proceeds from the financing will support a Phase 2/3 Alzheimer's clinical trial of NDX-1017. NDX-1017 is a small molecule therapeutic designed to enhance the activity of a naturally occurring repair mechanism that has the potential to restore neuronal health and brain function.

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

4000 Mason Rd. 300 Box 352141
Seattle, WA 98195
USA

Phone

(206) 221-8112

Website

www.athira.com

Email Address

[email protected]

Overview

Athira Pharma (Nasdaq: ATHA) is a drug development company striving to improve human health by advancing new therapies for neurodegenerative diseases like Alzheimer's and Parkinson's. Our innovative approach is focused on turning brain degeneration into regeneration, achieved by re-establishing lost connections and restoring lost function.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Leen Kawas

Chief Financial Officer

Glenna Mileson

Chief Operating Officer

Mark Litton

VP - Bus. Development

Josh Pan

VP - General Counsel

Christina Thomson

VP - R & D

Xue Hua

Browse more venture capital transactions:

Prev: 6/4/2020: BetterView venture capital transaction
Next: 6/5/2020: Routinify venture capital transaction

Share this article

About Our Venture Capital Transactions Database

We do our best to document every notable VC transaction. VC investment data records reported here are derived from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary